Preclinical, Publications ALG-125755, a Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model
Preclinical, Publications Capsid Assembly Modulator ALG-000111 and its Prodrug ALG-000286 Display Excellent In Vitro and In Vivo Antiviral Activity
ALG-000184, Publications Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity of Multiple Doses of ALG-000184 in Healthy Volunteers (HV) and Subjects with Chronic Hepatitis B (CHB)
Publication, Publications ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
Publication, Publications Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics
Preclinical, Publications The 3CLpro™ Inhibitor ALG-097111 Potently Inhibits SARS-CoV-2 Replication in Hamsters
Publication, Publications Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development
ALG-000184, Publications Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of ALG-000184, a Class II Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B (CHB), in Healthy Volunteers (HV)
ALG-000184, Publications Excellent preclinical characteristics of ALG-000184, a prodrug of the HBV capsid assembly modulator ALG-001075